Generic filters
Filter by content type
Taxonomy terms

BRTX – BioRestorative Therapies Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 37

Low: 37

High: 37

Total Analysts: 0

Company Profile

BioRestorative Therapies, Inc. is a life sciences company, which is focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. It offers two developmental programs, namely Disc/Spine Program (brtxDisc) and Metabolic Program (ThermoStem), which relate to the treatment of disc/spinedisease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous hypoxic cultured mesenchymal stem cell (MSC) product derived from a patient’s own bone marrow and formulated with a biomaterial carrier (platelet lysate). BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. It is engaged in developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (BADSC), to generate brown adipose tissue (BAT).

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan